Citigroup raised its price objective and issued a buy rating for EyePoint Pharmaceuticals, which trades on Nasdaq.
3 reports, 2 independent
Updated Aug 19
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup raised its price objective and issued a buy rating for EyePoint Pharmaceuticals, which trades on Nasdaq.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.RBC adjusted its rating and Citigroup raised its price objective for EyePoint Pharmaceuticals.1 source
Citigroup issued a buy rating for EyePoint Pharmaceuticals stock.1 source
Keep exploring
The entities involved
-
EyePoint Pharmaceuticals (United Kingdom)
company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery
-
Citigroup
American investment bank and financial services corporation
Related events
- Citigroup raised its price objective on the shares of Integer Holdings Corporation on September 1, 2026.
- Citigroup and Truist Financial issued buy ratings and increased price targets for Cisco.
- Citigroup raised shares to a buy rating for Fisher & Paykel Healthcare.
- Bank of America raised its buy rating and price objective, while Citigroup raised its target price and gave a neutral rating for Ford Motor Company.
- Citigroup boosted its price objective on Welltower shares.